Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.

What Was Tested

The paper reports a study of Anticholesteremic Agents in the context of fatty liver & elevated liver enzymes, published as a randomized controlled trial.

The aim of the present study was to investigate the relationship between hepatic antioxidant paraoxonase 1 (PON1) activity, lipid peroxidation and antioxidant enzymes in patients with NAFLD and the effect of atorvastatin.

Who Took Part

The study group was 50 patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

This study was conducted on 50 patients with NAFLD and 20 normal subjects matched for age and sex.

All of them were subjected to the following investigations: abdominal ultrasonography, serum PON1 activity level, liver function tests, serum lipid profile, fasting and postprandial blood glucose and serum levels of malondialdehyde (MDA) and glutathione peroxidase (GP).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Anticholesteremic Agents and who got the comparison, which limits bias.

NAFLD patients were further randomly classified into two groups (25 patients each), groups Ia and Ib.

What Was Measured

The subject headings attached to it are Alanine Transaminase, Anticholesteremic Agents, Aryldialkylphosphatase, Aspartate Aminotransferases, Atorvastatin, Cholesterol and Cross-Sectional Studies.

What This Means in Plain Language

The paper is a randomized study of Anticholesteremic Agents in 50 patients in people with fatty liver & elevated liver enzymes.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology), a journal based in Egypt.

More context: Fatty liver & elevated liver enzymes research.